Insulin glulisine: a faster onset of action compared with insulin lispro

Abstract

Glulisine shows a faster onset of action than lispro, independent of BMI and dose.

Efficacy and Safety of Insulin Glulisine in Intensive Insulin Therapy: Bolus Insulin Adjust Nice Control by apiDRA Study (BANDRA Study)

“…Therefore, Glu could ensure a good postprandial blood glucose control without development of preprandial hypoglycemia. Some previous reports described Glu to have a faster onset of action than Lis, independent of BMI and dose, in non-diabetic subjects [16] [17], and to achieve significant lower glucose level deviations than Lis in patients with type 2 diabetes [10].…”

Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine

“…In a cross-over comparison between insulin Glu and another rapidly-acting insulin analog, insulin Lispro (Lisp), Luzio et al found that the mean of three maximal preprandial subtracted plasma glucose concentrations (∆GLU max ) was significantly lower and the mean postprandial plasma insulin concentration was significantly higher when insulin Glu was injected before meals than when insulin Lisp was injected at the same time in type 2 diabetic patients [14]. Furthermore, evaluation by the glucose clamp method showed a faster onset of action for insulin Glu than insulin Lisp (0.2 U and 0.4 U/kg) in nondiabetic subjects [15]. These results suggest that insu-…”

Effects of rapid-acting insulin analogues insulin glulisine and insulin aspart on postprandial glycemic excursion with single bout of exercise in patients with type 2 diabetes

“…In addition, Glu has somewhat faster onset of action than Lis [10,11] and Asp [12,13] in obese participants with diabetes and healthy volunteers. The amino acid substitution of lysine to glutamic acid at position B29 allows Glu to have a slight faster onset of exposure (21 min for Glu, compared with 32 min for Asp and 31 min for Lis) and shorter mean duration of action (189 min for Glu, 194 min for Asp and 194 min for Lis) [8].…”

“…Slower absorption of insulin is observed with an increase in subcutaneous fat layer, and insulin sensitivity decreases due to the lipid burden related to increased visceral fat, requiring larger insulin doses in order to achieve sufficient glucose-lowering efficacy [16]. Heise et al reported in their crossover study that Glu showed a faster onset of action than Lis, independent of BMI and dose [10]. However, they made no mention of shorter duration of action.…”

“…Other studies used a different insulin regimen of 0.15-0.4 units/kg body weight [7,8,10,12,13]. In our study, the patients were administered the same insulin dose as they were accustomed to receiving every morning if they were treated with IIT, or 0.1 units/kg body weight if they were treated with OADs.…”